
Chimerix CMRX
Quartalsbericht 2024-Q3
hinzugefügt 07.11.2024
Chimerix Kurzfristige Verbindlichkeiten 2011-2025 | CMRX
Kurzfristige Verbindlichkeiten Jährlich Chimerix
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.4 M | 20.4 M | 29.9 M | 8.53 M | 9.23 M | 13 M | 13.2 M | 10.1 M | 20.2 M | 17.1 M | 10.2 M | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 29.9 M | 8.53 M | 15.5 M |
Kurzfristige Verbindlichkeiten anderer Aktien in der Pharmaeinzelhändler
| Name | Kurzfristige Verbindlichkeiten | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.76 | -0.73 % | $ 790 M | ||
|
Aclaris Therapeutics
ACRS
|
31.6 M | $ 3.01 | -1.15 % | $ 233 M | ||
|
Aeglea BioTherapeutics
AGLE
|
54.1 M | - | - | $ 1.01 B | ||
|
Alpine Immune Sciences
ALPN
|
58 M | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 1.16 | -0.85 % | $ 6.33 M | ||
|
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Aptevo Therapeutics
APVO
|
6.21 M | $ 0.52 | -44.08 % | $ 144 K | ||
|
BioVie
BIVI
|
2.27 M | $ 1.16 | -8.66 % | $ 1.71 M | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
72.8 M | - | -15.15 % | $ 60.3 M | ||
|
BioDelivery Sciences International
BDSI
|
82.4 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
174 M | $ 27.0 | 0.7 % | $ 1.31 B | ||
|
BeiGene, Ltd.
BGNE
|
2.21 B | - | 0.49 % | $ 251 B | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 0.22 | 24.23 % | $ 479 M | ||
|
Anika Therapeutics
ANIK
|
31.1 M | $ 9.49 | 0.11 % | $ 139 M | ||
|
Bellicum Pharmaceuticals
BLCM
|
3.77 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
45.5 M | - | -7.31 % | $ 87 M | ||
|
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | ||
|
Arena Pharmaceuticals
ARNA
|
66.3 M | - | -6.81 % | $ 3.04 B | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
Calithera Biosciences
CALA
|
14 M | - | -10.95 % | $ 876 K | ||
|
Axon Enterprise
AXON
|
1.68 B | $ 583.31 | -1.33 % | $ 44.2 B | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.47 | -2.37 % | $ 15.5 M | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Catalyst Biosciences
CBIO
|
20 M | $ 12.37 | - | $ 814 M | ||
|
Brickell Biotech
BBI
|
1.66 M | - | -5.38 % | $ 6.06 M | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
534 M | $ 10.71 | -0.88 % | $ 693 M | ||
|
Celldex Therapeutics
CLDX
|
39.5 M | $ 26.13 | -2.63 % | $ 1.68 M | ||
|
Biogen
BIIB
|
5.53 B | $ 176.07 | -0.15 % | $ 25.6 B | ||
|
Cellectar Biosciences
CLRB
|
25.4 M | $ 2.55 | -7.47 % | $ 31.2 M | ||
|
Cerevel Therapeutics Holdings
CERE
|
92.2 M | - | - | $ 7.29 B |